| NovoLog (insulin aspart) / Novo Nordisk |
2014-005657-39: Synnytyksen aikaisen sokeritasapainon vaikutus vastasyntyneen verensokeriin insuliinihoitoisilla raskausdiabeetikoilla |
|
|
| Ongoing | 4 | 50 | Europe | Concentrate and solvent for solution for injection/infusion, NovoRapid Penfill | Tampere University Hospital, Tampere University Hospital | Parturients having gestational diabetes, Parturients having gestational diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2014-004418-27: Can good blood glucose control be reached with a decision support system in patients who underwent stemm cell transplantation |
|
|
| Ongoing | 4 | 10 | Europe | Lantus, Solution for injection in pre-filled pen, Novorapid, Lantus | Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. f. Endokrinologie und Stoffwechsel, European Commission | Hyperglycaemic patients Patienten mit erhöhten Blutzuckerwerten, Patients with high blood glucose Patienten mit erhöhten Blutzuckerwerten, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Ongoing | 4 | 278 | Europe | Diformin retard, Protaphane Flexpen, Novorapid Flexpen, Humalog Pen, Diformin retard, Protaphane Flexpen, Novorapid Flexpen, Humalog Pen | Turku Univeristy Hospital | Raskausdiabetes | | | | |
2004-005019-28: Diabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucose |
|
|
| Ongoing | 4 | 6 | Europe | NovoRapid Aspartate, Rapeglinide, NovoRapid Aspartate, Rapeglinide | Papworth Hospital NHS Foundation Trust | Cystic fibrosis related diabetes mellitus | | | | |
2004-002170-34: \"Ensayo clínico controlado randomizado sobre el tratamiento precoz con insulina en recién nacidos de muy bajo peso\" |
|
|
| Ongoing | 4 | 60 | Europe | NovoRapid, NovoRapid, NovoRapid | Cambridge University Hospital (Addenbrookes Hospital) | Very low birth weight infants requiring intensive care have relative insulin deficiency often leading to hyperglycaemia during the first week of life. There is increasing evidence that the early postnatal period is critical for pancreatic development. This has implications both in terms of acute glucose control but also relative insulin deficiency is likely to play a role in poor postnatal growth, which has been associated with later motor and cognitive impairment. | | | | |
2005-003877-26: Comparison of the effect of insulin detemir and NPH insulin on dawn phenomenon in patients with Type 1 diabetes An open-labelled, randomised, cross-over, multi-center trial comparing the effect of insulin detemir versus NPH insulin as basal insulins on dawn phenomenon and the glycaemic control in patients with Type 1 diabetes treated on a basal-bolus regimen |
|
|
| Ongoing | 4 | 100 | Europe | Levemir, NovoRapid Penfill, Insulatard Penfill, Levemir, NovoRapid Penfill, Insulatard Penfill | National Centre for Diabetes Care, 1st Dept. Medicine, Diabetes Unit | Type 1 diabetes mellitus, dawn phenomenon | | | | |
2006-005846-35: COMPARISON OF TWO KINETICS OF ADMINISTRATION OF BOLUS BY INSULIN PORTABLE PUMP ON THE GLUCOSE BLOOD STABILITY FOR INSULIN-DEPENDENT PATIENTS |
|
|
| Ongoing | 4 | 50 | Europe | NA, NA, NovoRapid, NovoRapid | Centre Hospitalier Universitaire de Montpellier Direction Recherche, Qu | INSULIN-DEPENDENT PATIENTS USING AN INSULIN PORTABLE PUMP | | | | |
2006-005817-36: Ensayo Clínico en fase IV para la comparación entre dos pautas de tratamiento (insulina humana vs análogos de insulina) respecto al riesgo de hipoglicemia y la variabilidad del control glicémico en pacientes con diabetes mellitus tipo 1: impacto sobre el HYPO score y el LI (lability index). |
|
|
| Ongoing | 4 | 70 | Europe | Novorapid Flexpen, Lantus Optiset, Innolet Insulatard, Innolet Actrapid, Novorapid Flexpen, Lantus Optiset, Innolet Insulatard, Innolet Actrapid, Novorapid Flexpen, Lantus Optiset, Innolet Insulatard, Innolet Actrapid | Dr Manuel Pérez Maraver.Servicio de Endocrinologia. Hospital de Bellvitge | Diabetes mellitus tipo 1. Variabilidad del control glicémico y riesgo de hipoglicemia con una pauta de insulina basada en analogos respecto a una con insulina humana. | | | | |
2007-001590-29: Insulin aspart (NovoRapid®, Novo Nordisk) vs. human insulin (Actrapid®, Novo Nordisk) in intravenous treatment of high blood glucose concentrations in the ICU |
|
|
| Ongoing | 4 | 50 | Europe | NovoRapid, Actrapid, NovoRapid®,, Actrapid®, NovoRapid®,, Actrapid® | Herz-, Thorax- und Gefäßchirurgische Anästhesie und Intensivmedizin | Therapy of hyperglycemia by intravenously applied insulin is going to be investigated.Hyperglycemia is very common in hospitalized, critically ill patients, even if they have not previously had diabetes. Studies have established that in-hospital hyperglycemia is associated with higher mortality and morbidity. Therefore, careful monitoring and therapy of hyperglycemia have become standard in the ICU and include treatment with continuous infusion of insulin. | | | | |
2007-002773-30: Subcutaneous insulin therapy of hyperglycemia after initiation of oral intake in the ICU |
|
|
| Ongoing | 4 | 50 | Europe | NovoRapid, Levemir, NovoRapid, Levemir, NovoRapid, Levemir | Herz-, Thorax- und Gefäßchirurgische Anästhesie und Intensivmedizin | Hyperglycemia is very common in hospitalized, critically ill patients and is associated with higher mortality and morbidity. Careful monitoring and therapy of hyperglycemia have become standard in the ICU. Therapy of hyperglycemia by subcutaneously applied insulin after initiation of oral intake in the ICU is going to be investigated. | | | | |
2007-003085-17: The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes. |
|
|
| Ongoing | 4 | 30 | Europe | Levemir, Insulatard, NovoRapid, Levemir, Insulatard, NovoRapid | University of Surrey | Type 2 Diabetes Mellitus | | | | |
2008-004537-19: Effekt av insulininfusion på sjukdomsförloppet vid infekterade fotsår samt vid thorax- och kärlkirurgi hos patienter med diabetes |
|
|
| Ongoing | 4 | 80 | Europe | NovoRapid, NovoRapid | Karolinska Universitetssjukhuset | diabetes mellitus infekterat fotsårkärl eller thoraxkirurgisk operation | | | | |
2013-001791-38: Investigation of the resistance exerted by the tissue upon the insulin solution entering the tissue (hydraulic tissue resistance) at the site of administration and determine its relationship to the ability of the tissue to absorb the administered insulin |
|
|
| Ongoing | 4 | 10 | Europe | NovoRapid, NovoRapid | Medizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel, Medizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel | Diabetes Mellitus type 1 | | | | |
2014-002341-22: Testing Whether Glucagon Solutions Affect the Glucose Levels in the Fat Tissue of Diabetic Patients. Untersuchung der Wirkung von Glukagon-Präparaten auf den Glukosespiegel im Fettgewebe bei Patienten mit Typ 1 Diabetes. |
|
|
| Ongoing | 4 | 10 | Europe | Glucagon FOR INJECTION (rDNA ORIGIN), Eli Lilly Glucagon, GlucaGen, GLUCAGON FOR INJECTION (rDNA ORIGIN), NovoRapid, Actrapid, GlucaGen, GLUCAGON FOR INJECTION (rDNA ORIGIN), NovoRapid, Actrapid | Medizinische Universität Graz; Universitätsklinik für InnereMedizin; Abteilung für Endokrinologie und Stoffwechsel, Medizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel | Diabetes Mellitus type 1 | | | | |
2014-000980-42: Feasibility and safety of preoperative glucose control in patients with type 2 diabetes undergoing cardiovascular surgery |
|
|
| Ongoing | 4 | 40 | Europe | NovoRapid, EMEA/H/C/000258, Novo Rapid, Novo Rapid | Medical University Vienna, Medical University Vienna | The objective of this study is to investigate whether a targeted preoperative glucose control before planned cardiac surgery by i.v. insulin infusion (intensified glycemic control, ICG) versus standard care improves postoperative outcome in patients with T2DM. In addition to evaluating involved molecular mechanisms, this study should also strengthen the evidence of guidelines regarding perioperative glucose management of patients with T2DM. | | | | |
2016-002910-38: Basal and pre-meal insulin versus standard therapy for the inpatient manegement of type 2 diabetes: The IDA2 study Basal og bolus insulin versus standard behandling til indlagte patienter med type 2 diabetes: IDA2 studiet |
|
|
| Ongoing | 4 | 100 | Europe | Insulin degludec, insulin aspart, Suspension for injection in pre-filled pen, Solution for injection in pre-filled pen, Tresiba, Novorapid | Hvidovre University Hospital, Novo Nordisk A/S | Type 2 diabetes Type 2 diabetes, Type 2 diabetes Type 2 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2013-004737-33: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM Etude prospective randomisée multicentrique d’évaluation de la VILDagliptine associée à l’insuline sur le contrôle glycémique chez les patients hémoDIALysés diabétiques de type 2 : étude VILDDIAL |
|
|
| Not yet recruiting | 4 | 70 | Europe | Vildagliptine, Tablet, Solution for injection, Suspension for injection, Galvus, LANTUS 100 unités/ml solution injectable, LANTUS 100 unités/ml solution injectable en cartouche, LANTUS 100 unités/ml solution injectable en cartouche pour OptiClik, Lantus OptiSet 100 unités/ml solution injectable en stylo prérempli, Lantus SoloStar 100 unités/ml solution injectable en stylo prérempli, Levemir 100 U/ml, solution injectable en cartouche, Levemir 100 U/ml, solution injectable en stylo prérempli, Levemir InnoLet 100 U/ml, solution injectable en stylo prérempli, Levemir FlexTouch 100 U/ml, solution injectable en stylo prérempli, Apidra 100 unités/ml solution injectable en flacon, Apidra 100 unités/ml solution injectable en cartouche, Apidra 100 unités/ml solution injectable en cartouche pour OptiClik, Apidra 100 unités/ml solution injectable en stylo prérempli, Apidra SoloStar 100 unités/ml solution injectable en stylo prérempli, Humalog 100 UI/ml, solution injectable en flacon, Humalog 100 UI/ml, solution injectable en cartouche, Humalog Mix25 100 UI/ml suspension injectable en flacon, Humalog Mix25 100 UI/ml suspension injectable en cartouche, Humalog Mix50 100 UI/ml suspension injectable en flacon, Humalog Mix50 100 UI/ml suspension injectable en cartouche, Humalog BASAL 100 UI/ml suspension injectable en cartouche, Humalog Pen 100 UI/ml, solution injectable, Humalog Mix25 100 UI/ml Pen, suspension injectable, Humalog Mix50 100 UI/ml Pen, suspension injectable, Humalog BASAL 100 UI/ml Pen, suspension injectable, Humalog 100 UI/ml KwikPen, solution injectable, Humalog Mix25 100 UI/ml KwikPen, suspension injectable, Humalog Mix50 100 UI/ml KwikPen, suspension injectable, Humalog BASAL 100 UI/ml KwikPen, suspension injectable, NovoRapid 100 U/ml, solution injectable, NovoRapid Penfill 100 U/ml, solution injectable en cartouche, NovoRapid FlexPen 100 U/ml, solution injectable en stylo prérempli, NovoRapid InnoLet 100 U/ml, solution injectable en stylo prérempli, NovoRapid FlexTouch 100 U/ml, solution injectable en stylo prérempli | Hôpitaux Universitaires de Strasbourg, HÔPITAUX UNIVERSITAIRES DE STRASBOURG, NOVARTIS PHARMASAS | haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2015-003666-85: Investigation of Appropriate Timing of Additional Insulin Dosing for Fat and Protein in Children with Type 1 Diabetes using Multiple Daily Injections |
|
|
| Not yet recruiting | 4 | 40 | Europe | Insulin Aspart (NovoRapid), Solution for injection, Novorapid | Oxford University Hospitals NHS Trust, National Institute of Health Research funding from OUHT, NovoNordisk Research Foundation | Type 1 diabetes, Insulin-dependent diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2018-002646-36: Pilot study to evaluate blood sugar control with GlucoTab using a very long-acting insulin in non-critically ill type 2 diabetics at the general ward Pilotstudie, zur Bestimmung der Blutzucker Kontrolle mit GlucoTab unter Verwendung eines sehr lange wirkenden Insulins bei nicht kritisch kranken Typ 2 Diabetikern und Diabetikerinnen auf der Allgemeinstation |
|
|
| Ongoing | 4 | 30 | Europe | Insulin Degludec, Insulin NovoRapid, EMA/101455/2015, EMA/632418/2016, Solution for injection in pre-filled pen, Tresiba, NovoRapid | Medical University of Graz, Medical University of Graz | Diabetes Mellitus Type 2, Hyperglycaemia Diabetes Mellitus Typ 2, Hyperglykämie, Diabetes Mellitus Type 2, high blood sugar Zuckerkrankheit Typ 2, erhöhter Blutzucker, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2019-001281-14: A study that investigates the effects of fast-acting insulin (FIASP®) on blood sugars in comparison to a different fast-acting insulin (NovoRapid®) around exercise in participants with type 1 diabetes Der Einfluss von schnell-wirkendem Insulin (FIASP®) auf den Blutzuckerspiegel im Vergleich zu einem anderen schnell wirkendem Insulin (NovoRapid®) vor, während und nach sportlicher Belastung |
|
|
| Ongoing | 4 | 44 | Europe | Fiasp, Novorapid, Tresiba, A10AB05, Injection, Fast-acting insulin aspart (Fiasp® 100 U/mL) in 3 mL FlexTouch®, Insulin aspart (NovoRapid® 100 U/mL) in 3 mL FlexPen®, Insulin degludec (Tresiba® 100 U/mL) in 3 mL FlexTouch® | Medical University of Graz, Novo Nordisk | Type 1 Diabetes Typ 1 Diabetes Mellitus, Participants in this study have type 1 diabetes which is defined as the lack of own insulin production. Probanden in dieser Studie haben Typ 1 Diabetes Mellitus welches sich durch das Ausbleiben einer körpereigenen Insulinproduktion auszeichnet., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
PLATEAU, NCT04414579: The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus |
|
|
| Recruiting | 4 | 45 | US | Faster Insulin Aspart (Fiasp®), Conventional Insulin Aspart (NovoLog®) | Mountain Diabetes and Endocrine Center | Type 1 Diabetes Mellitus | 03/21 | 03/21 | | |
NCT04124302: The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. |
|
|
| Not yet recruiting | 4 | 70 | NA | Insulin Glulisine, Apidra, Insulin Aspart, NovoRapid, Insulin Lispro, Humalog, Liprolog | Medical University of Warsaw | Diabetes Mellitus, Type 1 | 08/21 | 08/23 | | |
NCT04019821: Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal |
|
|
| Completed | 4 | 72 | Europe | Insulin Glulisine, Apidra, Insulin Aspart, NovoRapid, Insulin Lispro, Humalog, Liprolog | Medical University of Warsaw | Diabetes Mellitus, Type 1 | 01/23 | 04/23 | | |
2022-003537-18: Investigation of the resistance of the tissue to the introduction of an insulin solution (tissue hydraulic resistance) and determination of its relationship to the ability of the tissue to absorb the introduced insulin |
|
|
| Not yet recruiting | 4 | 22 | Europe | Solution for injection/infusion, NovoRapid | Medizinische Universität Graz, Medizinische Universität Graz | Diabetes Mellitus type 1, Metabolic disease in which a person has high blood sugar because the body does not produce enough insulin, Diseases [C] - Hormonal diseases [C19] | | | | |
TRANSITION-T2D, NCT04538352: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus |
|
|
| Completed | 4 | 60 | US | Semaglutide, Ozempic, Insulin Degludec, Tresiba, Insulin aspart, Novolog | The Cleveland Clinic, Novo Nordisk A/S | Type 2 Diabetes | 03/23 | 11/23 | | |
2020-001158-23: Fast-Acting Insulin Aspart and Insulin Pump Settings:“THE FAST PUMP SETTING STUDY” |
|
|
| Not yet recruiting | 4 | 40 | Europe | Fiasp, Novorapid, Solution for injection/infusion, Fiasp, NovoRapid | Steno Diabetes Center Copenhagen, Steno Diabetes Center Copenhagen, Novo Nordisk A/S | Type 1 diabetes, Participants in this study have type 1 diabetes which is defined as lack of own insulin production Type 1 diabetes er en kronisk sygdom som er karakteriseret ved at man ikke kan producere insulin til at få blodglukose ned., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Recruiting | 4 | 260 | US | Oral Anti-diabetes Drugs alone, metformin, sulfonylureas, pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, Basal bolus insulin, glargine, detemir, Supplemental insulin, Humalog, Novolog, Continuous glucose monitoring (CGM), Dexcom | Emory University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus | 09/24 | 12/24 | | |
MIRE, NCT04381429: Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes |
|
|
| Recruiting | 4 | 40 | Europe | A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP), All patients will have both treatments: NovoRapid + FIASP, F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid) | University Hospital, Strasbourg, France | Cystic Fibrosis-related Diabetes | 08/25 | 08/25 | | |
ChiCTR2000031290: A 24-Week, Open-label, Randomized, Multicenter, Phase III Study to Compare the Efficacy and Safety of Gan & Lee Injection (Ruixiulin) to NovoRapid?, Both in Combination with Metformin in Adult Subjects with Type 1 or Type 2 Diabetes |
|
|
| Not yet recruiting | 3 | 592 | | Gan & Lee Injection (Ruixiulin) + Metformin versus NovoRapid + Metformin | Peking University First Hospital; Gan&Lee Pharmaceuticals, Self-funding | Diabetes Milletus | | | | |
2006-000306-23: A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere®/Insulin Versus Subcutaneous Basal Insulin and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow-up |
|
|
| Ongoing | 3 | 30 | Europe | Technosphere®/Insulin, Lantus 100 IU/ml, NovoRapid 100 U/ml, Lantus 100 IU/ml, NovoRapid 100 U/ml, Lantus 100 IU/ml, NovoRapid 100 U/ml | MannKind Corporation | Diabetes mellitus type I | | | | |
2010-023792-25: A randomised controlled trial of continuous subcutaneous insulin infusion(CSII) compared to multiple daily injection(MDI) regimens on insulin in children and young people at diagnosis of type I diabetes mellitus (TIDM). |
|
|
| Ongoing | 3 | 316 | Europe | Insulin Glargine, Insulin Aspart, Lantus 100 units/ml solution for injection in a cartridge Lantus 100 units/ml solution for injection in a pre-filled pen(optiset), NovoRapid 100 U/ml solution for injection in vial. NovoRapid Penfill 100 U/ml solution for injection in cartridge. NovoRapid Flexpen 100 U/ml solution for injection in prefilled pen., Lantus 100 units/ml solution for injection in a cartridge Lantus 100 units/ml solution for injection in a pre-filled pen(optiset), NovoRapid 100 U/ml solution for injection in vial. NovoRapid Penfill 100 U/ml solution for injection in cartridge. NovoRapid Flexpen 100 U/ml solution for injection in prefilled pen. | Alder Hey Children\'s NHS Foundation Trust | Type 1 Diabetes Mellitus | | | | |
2010-022246-25: Diagnostic clinique et mécanismes physiopathologiques de l'allergie à l'insuline. |
|
|
| Not yet recruiting | 3 | 70 | Europe | Actrapid, Insulatard, Insuman Infusat, Humalog, NovoRapid, Apidra, Lantus, Levemir, Latex, Solution for injection, Suspension for injection, Solution for infusion, Actrapid, Insulatard, Novorapid, Levemir | | Allergie à l'insuline | | | | |
2016-001401-16: The SUGAR-DIP trial: Oral medication versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie versus insuline voor zwangerschapsdiabetes |
|
|
| Ongoing | 3 | 810 | Europe | Metformin, Glibenclamide, Tablet, Injection, Metformin, Glibenclamide, Insulin: including - fast acting, analog: NovoRapid, Humalog, Apidra - short acting, human: Actrapid, Humuline Regular, Insuman Rapid - medium long acting, human: Insulatard, Humuline NPH, Insuman Basal - long acting analog: Lantus, Levemir | University Medical Center Utrecht, ZonMw | The medical condition to be investigated in this trial is gestational diabetes with insufficient glycemic control by means of dietary adjustments and thus an indication for addiotional pharmacological treatment. In deze trial wordt het ziektebeeld diabetes gravidarum onderzocht, waarbij er met dieetaanpassingen onvoldoende glucosecontrole is bereikt en er dus indicatie is voor aanvullende farmacologische behandeling., Gestational diabetes, also known as gestational diabetes mellitus, is a condition in which women without previously diagnosed diabetes exhibit high blood glucose (blood sugar) levels during pregnancy. Zwangerschapssuikerziekte, ook wel zwangerschapsdiabetes, is een aandoening waarbij vrouwen waarbij niet al eerder suikerziekte is vastgesteld, tijdens de zwangerschap hoge bloedsuikerwaardes hebben., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
Recombinant Insulin Aspart, ChiCTR2000034886: Multicenter, randomized, open, and positive parallel controlled, Phase III clinical trial to evaluate the efficacy and safety of recombinant Insulin Aspart injection (HS005) and NovoRapid in the treatment of diabetes |
|
|
| Completed | 3 | 700 | | Type 1 diabetes: Glargine Insulin+ NovoRapid, HS005+ Glargine Insulin ;Type1 diabetes: Glargine Insulin+ NovoRapid, NovoRapid + Glargine Insulin ;Type II diabetes Glargine Insulin+Metformin Hydrochloride Tablets, HS005+ Glargine Insulin+Metformin Hydrochloride Tablets ;Type II diabetes Glargine Insulin+Metformin Hydrochloride Tablets, NovoRapid + Glargine Insulin+Metformin Hydrochloride Tablets | Nanjing Drum Tower hospital (the Affiliated Hospital of Nanjing University Medical School); ZHENGJIANG HISUN PHARMACEUTICAL Co., Ltd., Fully self-raised | Diabetes | | | | |
2018-004680-31: A comparison of the faster-acting insulin Fiasp® versus insulin Novorapid® in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation |
|
|
| Not yet recruiting | 3 | 220 | Europe | Solution for injection in pre-filled pen, Solution for injection/infusion, Fiasp, Novorapid | Lene Ringholm, Novo Nordisk | Type 1 and type 2 diabetes during pregnancy and lactation, Insulin requiring diabetes during pregnancy and lactation, Diseases [C] - Hormonal diseases [C19] | | | | |
2020-005309-18: A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3) Klinikai vizsgálat annak tanulmányozására, hogy az IcoSema, az ikodek inzulin és a szemaglutid kombinációjából álló, hetente alkalmazott új gyógyszer mennyire kontrollálja jól a 2-es típusú cukorbetegek vércukorszintjét a naponta, aszpart inzulinnal együtt alkalmazott glargin inzulinnal összehasonlítva (COMBINE 3) |
|
|
| Ongoing | 3 | 680 | Europe | IcoSema 700 U/mL + 2 mg/mL PDS290, Solution for injection in pre-filled pen, Solution for injection, Lantus SoloStar, NovoRapid FlexPen | Novo Nordisk A/S, Novo Nordisk A/S | Diabetes Mellitus, Type 2 2-es típusú diabétesz mellitus, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT03770767: Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes |
|
|
| Completed | 3 | 216 | Europe | Faster-acting Aspart insulin Fiasp, Insulin Fiasp, Control (insulin Novorapid), First generation insulin analog | Rigshospitalet, Denmark | Diabetes Mellitus, Pregnancy Complications | 03/23 | 03/23 | | |
NCT04460326: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 137 | US | Insulin glargine, Lantus®, NovoLog, NovoLog®, Insulin Fiasp, Fiasp®, Standard carbohydrate diet | Boston Medical Center, Novo Nordisk A/S | Type 2 Diabetes Treated With Insulin | 05/23 | 05/23 | | |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 09/24 | 04/25 | | |
NCT05539872: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers |
|
|
| Completed | 2/3 | 69 | US | I004, Insulin Aspart, a rapid-acting human insulin analogue, NovoLog | Amphastar Pharmaceuticals, Inc. | Pharmacokinetics, Pharmacodynamics | 01/23 | 01/23 | | |
2011-002780-16: A study of efficacy and safety of the glucose lowering drug Exenatide on patients with suspected acute stroke and hyperglycemia |
|
|
| Ongoing | 2 | 100 | Europe | Byetta, Novorapid, A10AB05, Solution for injection in pre-filled pen, Byetta, Novorapid | Karolinska Institutet, Karolinska institutet Södersjukhuset | Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of Byetta or standard care., Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of the glucose lowering drug Byetta or standard care against hyperglycemia., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2008-005263-34: The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY) 3. A 2 year, single-centre, open-label, randomised, parallel-group trial comparing insulin therapy to conventional oral sulphonyurea on beta-cell survival. |
|
|
| Ongoing | 2 | 40 | Europe | Diamicron, NovoRapid, Levemir, Diamicron, NovoRapid, Levemir, Diamicron, NovoRapid, Levemir | The Mater Foundation/HRB Grant | The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY ) 3. | | | | |
ChiCTR1800015107: The effects of lilalucopeptide combined with alendronate on bone mineral density and serum BGP, s-ctx and BAP levels in patients with type 2 diabetes mellitus and osteoporosis. |
|
|
| Not yet recruiting | 1 | 80 | | Lilalupeptide combined with alendronate sodium therapy. ;Novorapid 30 combined with alendronate sodium. | Gansu Province Hospital of TCM; Gansu province hospital of TCM, Gansu health and family planning commission. | Type 2 diabetes | | | | |
NCT05737576: The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject |
|
|
| Completed | 1 | 61 | RoW | HR011408 injection; NovoRapid®, NovoRapid®；HR011408 injection | Jiangsu HengRui Medicine Co., Ltd. | Diabetes | 10/23 | 12/23 | | |
NCT05719961: Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | INS062 injection, Insulin Aspart, HR20014 injection, Insulin Aspart 30 Injection | Jiangsu HengRui Medicine Co., Ltd. | Diabetes | 07/23 | 07/23 | | |
NCT05754424: AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study |
|
|
| Completed | 1 | 41 | Europe | AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution | Arecor Limited | Diabetes Mellitus, Type 2 | 01/24 | 02/24 | | |
NCT06375031: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics |
|
|
| Recruiting | 1 | 30 | RoW | HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection | Jiangsu HengRui Medicine Co., Ltd. | Diabetes | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 150 | RoW | Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine | Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull | Diabetes Mellitus Type 2 | 10/23 | 10/24 | | |
NCT04965051: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM |
|
|
| Recruiting | N/A | 40 | RoW | insulin degludec/insulin aspart (IDegAsp), Ryzodeg, basal insulin plus pre-prandial insulin, Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra | Second Affiliated Hospital, School of Medicine, Zhejiang University | Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range | 12/23 | 12/23 | | |
NCT05417841: Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM |
|
|
| Not yet recruiting | N/A | 224 | RoW | Insulin Degludec and Insulin Aspart Injection, Ryzodeg®, Insulin Aspart Injection, NovoRapid® | Beijing Hospital | Type 2 Diabetes Mellitus | 12/23 | 07/24 | | |
| Recruiting | N/A | 24 | | | NW Cheung | Diabetes mellitus | | | | |